Roche to return type II diabetes drug development rights to Chugai
Chugai has licensed marketing and development rights for CSG452 to Roche in January 2007 as a treatment for type II diabetes. Roche’s decision was backed by the priority
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).